Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fry

Showing results (181-190 of 201) with videos related to

Pageof 21
Sort By:
Journal of Medicinal Chemistry|March 26, 1998
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factorsG W Rewcastle, D K Murray, W L Elliott, et al.
Journal of Medicinal Chemistry|July 21, 2001
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptorJ B Smaill, H D Showalter, H Zhou, et al.
Physical Review Letters|March 16, 2007
Nuclear spin switch in semiconductor quantum dotsA I Tartakovskii, T Wright, A Russell, et al.
Journal of Medicinal Chemistry|April 2, 2005
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6Peter L Toogood, Patricia J Harvey, Joseph T Repine, et al.
The Mount Sinai Journal of Medicine, New York|November 21, 2008
Diversity in academic medicine no. 5 successful programs in minority faculty development: overviewAnn-Gel S Palermo, Maria L Soto-Greene, Vera S Taylor, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 16, 2024
Amoebozoan testate amoebae illuminate the diversity of heterotrophs and the complexity of ecosystems throughout geological timeAlfredo L Porfirio-Sousa, Alexander K Tice, Luana Morais, et al.
Physical Review Letters|October 4, 2000
Inverted electron-hole alignment in InAs-GaAs self-assembled quantum dotsP W Fry, I E Itskevich, D J Mowbray, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 30, 1998
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitorD W Fry, A J Bridges, W A Denny, et al.
The Journal of Experimental Medicine|April 26, 2022
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissueZhi Li, Zewen K Tuong, Isaac Dean, et al.
Journal of Medicinal Chemistry|February 14, 1997
Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congenersH D Showalter, A D Sercel, B M Leja, et al.
Pageof 21

Showing results (181-190 of 201) with videos related to

Sort By:
Pageof 21
Journal of Medicinal Chemistry|March 26, 1998
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factorsG W Rewcastle, D K Murray, W L Elliott, et al.
Journal of Medicinal Chemistry|July 21, 2001
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptorJ B Smaill, H D Showalter, H Zhou, et al.
Physical Review Letters|March 16, 2007
Nuclear spin switch in semiconductor quantum dotsA I Tartakovskii, T Wright, A Russell, et al.
Journal of Medicinal Chemistry|April 2, 2005
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6Peter L Toogood, Patricia J Harvey, Joseph T Repine, et al.
The Mount Sinai Journal of Medicine, New York|November 21, 2008
Diversity in academic medicine no. 5 successful programs in minority faculty development: overviewAnn-Gel S Palermo, Maria L Soto-Greene, Vera S Taylor, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 16, 2024
Amoebozoan testate amoebae illuminate the diversity of heterotrophs and the complexity of ecosystems throughout geological timeAlfredo L Porfirio-Sousa, Alexander K Tice, Luana Morais, et al.
Physical Review Letters|October 4, 2000
Inverted electron-hole alignment in InAs-GaAs self-assembled quantum dotsP W Fry, I E Itskevich, D J Mowbray, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 30, 1998
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitorD W Fry, A J Bridges, W A Denny, et al.
The Journal of Experimental Medicine|April 26, 2022
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissueZhi Li, Zewen K Tuong, Isaac Dean, et al.
Journal of Medicinal Chemistry|February 14, 1997
Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congenersH D Showalter, A D Sercel, B M Leja, et al.
Pageof 21